All In Biotech

Investigational drug · Phase 3

H1 receptor antagonist

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

249

Any phase or sponsor naming "H1 receptor antagonist"

First trial start

2024

Jun 11, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "H1 receptor antagonist", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Lung Neoplasm Malignant
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
  • Non-small Cell Lung Cancer (NSCLC)

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "H1 receptor antagonist" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1,376 on PubMed

Also in development for Lung Neoplasm Malignant

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • MK-1084CalderasibPhase 38 trials

    Merck & Co. · Non-small Cell Lung Cancer, Colon Adenocarcinoma, Rectal Adenocarcinoma

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.